| |
|
Product Name:
|
Mouse-Adapted, MA10 Variant (in Isolate USA-WA1/2020 Backbone), Infectious Clone (ic2019-nCoV MA10) in VTA Cells
|
|
Manufacturer:
|
BEI Resources
|
|
Taxonomy:
|
Virus Classification: Coronaviridae, Betacoronavirus Species: Severe acute respiratory syndrome-related coronavirus 2 Strain/Isolate: Infectious clone of isolate MA10 (ic2019-nCoV MA10)1,2
|
|
Additional Information:
|
In December 2019, an outbreak of a respiratory illness (COVID-19) began in Wuhan, Hubei Province, China. The outbreak is associated with a seafood market and although environmental samples from the market are positive for the novel coronavirus, an association with a particular animal has not been determined.6
|
|
Material Provided:
|
Each vial contains approximately 1 mL of cell lysate and supernatant from C. aethiops kidney epithelial cells expressing transmembrane protease serine 2 and human angiotensin-converting enzyme 2 (Vero E6-TMPRSS2-T2A-ACE2; VTA) infected with SARS-Related Coronavirus 2, Mouse Adapted, MA10 Variant (in Isolate USA-WA1/2020 Backbone), Infectious Clone (ic2019-nCoV MA10).Note: If homogeneity is required for your intended use, please purify prior to initiating work. |
|
Packing/Storage:
|
NR-60440 was packaged aseptically in cryovials. The product is provided frozen and should be stored at -80°C or colder immediately upon arrival. For long-term storage, the vapor phase of a liquid nitrogen freezer is recommended. Freeze-thaw cycles should be avoided.
|
|
Growth Conditions:
|
Host: C. aethiops kidney epithelial cells expressing transmembrane protease serine 2 and human angiotensin-converting enzyme 2 (Vero E6-TMPRSS2-T2A-ACE2; VTA) Growth Medium: Eagle’s Minimum Essential Medium containing Earle’s Balanced Salt Solution, non-essential amino acids, 2 mM L-glutamine, 1 mM sodium pyruvate and 1.5 g/L of sodium bicarbonate supplemented with 2% fetal bovine serum, or equivalent Infection: Cells should be 70% to 80% confluent Incubation: 2 to 5 days at 37°C and 5% CO2 Cytopathic Effect: Syncytia formation and sloughing
|
|
Disclaimers:
|
You are authorized to use this product for research use only. It is not intended for human use.Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org. While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate. This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.
|
References:
|
1. Baric, R. S., Personal Communication.2. Leist, S. R., et al. “A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice.” Cell 183 (2020): 1070-1085. PubMed: 33031744.
3. Dinnon, H. K., et al. “SARS-COV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract.” Cell 182 (2020): 429-446. PubMed: 32526206.
4. Rambaut, A., et al. “A Dynamic Nomenclature Proposal for SARS-CoV-2 Lineages to Assist Genomic Epidemiology.” Nat. Microbiol. 5 (2020): 1403-1407. PubMed: 32669681.
5. Mercatelli, D. and F. M. Giorgi. “Geographic and Genomic Distribution of SARS-CoV-2 Mutations.” Front. Microbiol. (2020): doi.org/10.3389/fmicb.2020.01800. PubMed: 32793182.
6. Gralinski, L. E. and V. D. Menachery. “Return of the Coronavirus: 2019-nCoV.” Viruses 12 (2020): 135. PubMed: 31991541. |
|
Citation:
|
Acknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: SARS-Related Coronavirus 2, Mouse-Adapted, MA10 Variant (in Isolate USA-WA1/2020 Backbone), Infectious Clone (ic2019-nCoV MA10) in VTA Cells, NR-60440, contributed by Ralph S. Baric.”
|
|
Biosafety Level:
|
2
Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories (BMBL). Current Edition. Washington, DC: U.S. Government Printing Office.
|